This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
What's in Store for Becton, Dickinson's (BDX) Q4 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) fiscal fourth-quarter results likely to reflect robust performance at BD Life Sciences.
Analysts Estimate Becton Dickinson (BDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Dental Supplies Stocks Set to Shine on the Industry's Upturn
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. CAH, WST and MCK are well positioned to gain from the prospects.
LabCorp (LH) Extends Pact With Swedish for Coronavirus Lab Service
by Zacks Equity Research
Under the extended alliance, LabCorp (LH) expects to expand its COVID-19 test capacity in the Seattle area.
BD's (BDX) COVID-19 Real-Time PCR Detection Kit Gets CE Mark
by Zacks Equity Research
BD's (BDX) Real Time PCR Detection Kit enables BD MAX System users to run a single module that tests concurrently for COVID-19, flu and RSV.
OPKO Health's (OPK) BioReference Laboratories Unveils New Test
by Zacks Equity Research
OPKO Health's (OPK) BioReference Laboratories' new multiplex test can differentiate between COVID-19 and Influenza infections with a single sample.
BD Gets 510(k) Clearance for Its FACSLyric Flow Cytometer
by Zacks Equity Research
BD (BDX) gets 510(k) clearance from the FDA for its new integrated system that helps clinical laboratories to fully automate the sample to answer process and boost their efficiency.
BD Gets CE Mark for Point-of-Care Coronavirus Antigen Test
by Zacks Equity Research
BD (BDX) receives CE mark for its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor Plus System.
Quest Diagnostics' 3-in-1 Coronavirus Test Launch Well Timed
by Zacks Equity Research
According to Quest Diagnostics (DGX), under such situation, laboratory testing that can reliably identify the virus causing disease will be critical to mobilize effective patient care.
7 Diagnostic and Genomic Stocks Storming Into October
by Kevin Cook
COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.
3 Great MedTech Stocks to Pick Amid the Coronavirus Crisis
by Sriparna Ghosal
Backed by projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.
Coronavirus Test Makers With Scope to Maximize Investor Benefits
by Urmimala Biswas
The surge in new coronavirus infections broadens the scope for antigen and antibody tests.
Becton Dickinson (BDX) Down 9.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Abbott Lab, Quidel, Becton, Dickinson and Company, Hologic and Quest Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Lab, Quidel, Becton, Dickinson and Company, Hologic and Quest Diagnostics
Price War in Coronavirus Test Space to Intensify Thanks to Abbott
by Urmimala Biswas
Most rapid antigen tests in the United States require an additional system, which is making the procedures more costly and complex.
Company News for Aug 7, 2020
by Zacks Equity Research
Companies In The News: BMY, CRON, BDX, LNG.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q3
by Zacks Equity Research
Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in Q3.
Becton Dickinson (BDX) Q3 Earnings Beat Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 7.32% and -1.88%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Becton, Dickinson (BDX) Might Surprise This Earnings Season
by Zacks Equity Research
Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Becton, Dickinson's (BDX) Q3 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) fiscal third-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.
Becton Dickinson (BDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BD Collaborates With BARDA to Combat Coronavirus Crisis
by Zacks Equity Research
Becton, Dickinson (BDX) forms a strategic public-private partnership with BARDA to help the U.S. government in its efforts to fight the COVID-19 pandemic and future pandemics.
BD Receives EUA for New Antigen Test to Combat COVID-19
by Zacks Equity Research
Becton, Dickinson (BDX) receives EUA from the FDA for a rapid, point-of-care, antigen test to detect SARS-CoV-2 in 15 minutes.
BD Unveils BD PurPrep Patient Preoperative Skin Preparation
by Zacks Equity Research
By developing fully sterile PurPrep, BD (BDX) is offering health care experts a more complete set of tools to mitigate the risk of intrinsic contamination in antiseptic solutions.